NCT02687490View on ClinicalTrials.gov

Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

February 24, 2017

Primary Completion Date

December 1, 2020

Study Completion Date

December 15, 2020

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Abraxane

125 mg/m2, D1, D8, D15

Trial Locations (1)

200032

Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT02687490 - Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter